Physician profile
Chul So Moon
NPI 1316999055
$1,945.16
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2021: $576 · 2022: $171 · 2023: $363 · 2024: $56.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $194.77 | 2019 | |
| Amgen INC. | $152.14 | 2019-2023 | Kyprolis, Blincyto |
| Merck Sharp & Dohme LLC | $112.46 | 2021-2024 | Keytruda, Welireg, Lynparza |
| Genzyme Corporation | $106.52 | 2019-2023 | |
| Rigel Pharmaceuticals, INC. | $86.63 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $84.65 | 2019-2023 | Epkinly, Imbruvica |
| Novartis Pharmaceuticals Corporation | $81.83 | 2019-2024 | |
| Daiichi Sankyo INC. | $81.34 | 2021-2023 | Enhertu |
| Coherus Oncology, INC. | $78.40 | 2021 | |
| Seagen INC. | $76.83 | 2019-2023 | Adcetris |
| Pfizer INC. | $73.78 | 2019-2024 | |
| Janssen Biotech, INC. | $65.61 | 2021-2023 | Erleada |
| Genentech USA, INC. | $58.33 | 2019-2023 | Tecentriq, Alecensa, Perjeta |
| Exelixis INC. | $55.69 | 2019-2023 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $47.88 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44.48 | 2019-2023 | Jakafi |
| Puma Biotechnology, INC. | $37.94 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.91 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.89 | 2021-2023 | Libtayo |
| Emd Serono, INC. | $33.27 | 2021-2023 | Bavencio |
| Beigene USA, INC. | $32.67 | 2022 | |
| Celgene Corporation | $32.29 | 2019 | |
| Pharmacosmos Therapeutics INC. | $31.43 | 2021 | |
| Clovis Oncology, INC. | $28.46 | 2019 | |
| Taiho Oncology, INC. | $27.80 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $26.95 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $25.72 | 2019 | |
| Tactile Systems Technology INC | $21.13 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.02 | 2023 | Tazverik |
| Gilead Sciences, INC. | $20.49 | 2022 | |
| Deciphera Pharmaceuticals INC. | $19.17 | 2021 | |
| Apellis Pharmaceuticals, INC. | $17.92 | 2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $17.60 | 2023 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $17.36 | 2021 | |
| Abbvie INC. | $16.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.55 | 2021 | |
| Glaxosmithkline, LLC. | $14.93 | 2021 | |
| Lilly USA, LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chul So Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.